An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron
Authors
Keywords
-
Journal
Nature Microbiology
Volume 7, Issue 5, Pages 716-725
Publisher
Springer Science and Business Media LLC
Online
2022-04-27
DOI
10.1038/s41564-022-01119-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron
- (2022) Huiping Shuai et al. NATURE
- Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
- (2022) Lihong Liu et al. NATURE
- Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19
- (2022) Yuto Unoh et al. JOURNAL OF MEDICINAL CHEMISTRY
- Host and viral determinants for efficient SARS-CoV-2 infection of the human lung
- (2021) Hin Chu et al. Nature Communications
- Targeting the Main Protease of SARS‐CoV‐2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors
- (2021) Julian Breidenbach et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model
- (2021) Jingxin Qiao et al. SCIENCE
- Antivirals with common targets against highly pathogenic viruses
- (2021) Lu Lu et al. CELL
- Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors
- (2021) Naoya Kitamura et al. JOURNAL OF MEDICINAL CHEMISTRY
- SARS-CoV-2 variants, spike mutations and immune escape
- (2021) William T. Harvey et al. NATURE REVIEWS MICROBIOLOGY
- Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2
- (2021) Nir Drayman et al. SCIENCE
- Targeting highly pathogenic coronavirus-induced apoptosis reduces viral pathogenesis and disease severity
- (2021) Hin Chu et al. Science Advances
- Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity
- (2021) Chunlong Ma et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
- (2021) Dafydd R. Owen et al. SCIENCE
- Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19
- (2021) Britton Boras et al. Nature Communications
- Emerging SARS-CoV-2 variants expand species tropism to murines
- (2021) Huiping Shuai et al. EBioMedicine
- Deuterium-Enabled Chiral Switching (DECS) Yields Chirally Pure Drugs from Chemically Interconverting Racemates
- (2020) Sheila DeWitt et al. ACS Medicinal Chemistry Letters
- Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
- (2020) Zhenming Jin et al. NATURE
- Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
- (2020) Wenhao Dai et al. SCIENCE
- Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
- (2020) Linlin Zhang et al. SCIENCE
- Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period
- (2020) Stephen M. Kissler et al. SCIENCE
- Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
- (2020) Chunlong Ma et al. CELL RESEARCH
- Differential immune activation profile of SARS-CoV-2 and SARS-CoV infection in human lung and intestinal cells: Implications for treatment with IFN-β and IFN inducer
- (2020) Huiping Shuai et al. JOURNAL OF INFECTION
- SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function
- (2020) Emma S. Winkler et al. NATURE IMMUNOLOGY
- SARS-CoV-2 Induces a More Robust Innate Immune Response and Replicates Less Efficiently Than SARS-CoV in the Human Intestines: An Ex Vivo Study With Implications on Pathogenesis of COVID-19
- (2020) Hin Chu et al. Cellular and Molecular Gastroenterology and Hepatology
- Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice
- (2020) Fatai S. Oladunni et al. Nature Communications
- Applications of deuterium in medicinal chemistry
- (2019) Tracey Pirali et al. JOURNAL OF MEDICINAL CHEMISTRY
- Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies
- (2015) Renato A. Bauer DRUG DISCOVERY TODAY
- From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design
- (2014) Rolf Hilgenfeld FEBS Journal
- How good are my data and what is the resolution?
- (2013) Philip R. Evans et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Towards automated crystallographic structure refinement withphenix.refine
- (2012) Pavel V. Afonine et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Discovery, Synthesis, And Structure-Based Optimization of a Series of N-(tert-Butyl)-2-(N-arylamido)-2-(pyridin-3-yl) Acetamides (ML188) as Potent Noncovalent Small Molecule Inhibitors of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 3CL Protease
- (2012) Jon Jacobs et al. JOURNAL OF MEDICINAL CHEMISTRY
- XDS
- (2010) Wolfgang Kabsch ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Features and development ofCoot
- (2010) P. Emsley et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started